Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011:2011:865870.
doi: 10.1155/2011/865870. Epub 2011 Apr 6.

The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future

S E Richardson  1 , C McNamara
Affiliations

The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future

S E Richardson et al. Adv Hematol. 2011.

Abstract

The management of classical Hodgkin's lymphoma (CHL) is a success story of modern multi-agent haemato-oncology. Prior to the middle of the twentieth century CHL was fatal in the majority of cases. Introduction of single agent radiotherapy (RT) demonstrated for the first time that these patients could be cured. Developments in chemotherapy including the mechlorethamine, vincristine, procarbazine and prednisolone (MOPP) and Adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) regimens have resulted in cure rates of over 80%. Even in relapse, CHL patients can be salvaged with high dose chemotherapy and autologous haematopoietic stem cell transplantation (ASCT). Challenges remain, however, in finding new strategies to manage the small number of patients who continue to relapse or progress. In addition, the young age of many Hodgkin's patients forces difficult decisions in balancing the benefit of early disease control against the survival disadvantage of late toxicity. In this article we aim to summarise past trials, define the current standard of care and appraise future developments in the management of CHL.

PubMed Disclaimer

References

    1. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. New England Journal of Medicine. 1998;339(21):1506–1514. - PubMed
    1. Henry-Amar M, Aeppli DM, Anderson J, et al. Long term survival and study of causes of death. In: Somers R, Henry-Amar M, Meerwaldt JK, Carde P, editors. Treatment Strategy in Hodgkin’s Disease. London, UK: John Libbey and Co; 1990. pp. 381–418.
    1. Press OW, LeBlanc M, Lichter AS, et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin’s disease. Journal of Clinical Oncology. 2001;19(22):4238–4244. - PubMed
    1. Engert A, Franklin J, Eich HT, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. Journal of Clinical Oncology. 2007;25(23):3495–3502. - PubMed
    1. Noordijk EM, Carde P, Dupouy N, et al. Combined-modality therapy for clinical stage I or II Hodgkin’s lymphoma: long-term results of the European organisation for research and treatment of cancer H7 randomized controlled trials. Journal of Clinical Oncology. 2006;24(19):3128–3135. - PubMed

LinkOut - more resources